

Quinn T Ostrom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8841876/publications.pdf>

Version: 2024-02-01

120
papers

30,958
citations

57758

44
h-index

22166

113
g-index

124
all docs

124
docs citations

124
times ranked

28825
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-------|-----------|
| 1 | CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010. <i>Neuro-Oncology</i> , 2013, 15, ii1-ii56. | 1.2 | 5,799 |
| 2 | The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , 2013, 155, 462-477. | 28.9 | 3,979 |
| 3 | CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012â€“2016. <i>Neuro-Oncology</i> , 2019, 21, v1-v100. | 1.2 | 1,735 |
| 4 | CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. <i>Neuro-Oncology</i> , 2015, 17, iv1-iv62. | 1.2 | 1,727 |
| 5 | Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. <i>Cell</i> , 2016, 164, 550-563. | 28.9 | 1,695 |
| 6 | CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011â€“2015. <i>Neuro-Oncology</i> , 2018, 20, iv1-iv86. | 1.2 | 1,624 |
| 7 | The epidemiology of glioma in adults: a "state of the science" review. <i>Neuro-Oncology</i> , 2014, 16, 896-913. | 1.2 | 1,586 |
| 8 | CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. <i>Neuro-Oncology</i> , 2014, 16, iv1-iv63. | 1.2 | 1,253 |
| 9 | CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010â€“2014. <i>Neuro-Oncology</i> , 2017, 19, v1-v88. | 1.2 | 1,236 |
| 10 | CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013â€“2017. <i>Neuro-Oncology</i> , 2020, 22, iv1-iv96. | 1.2 | 1,175 |
| 11 | CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009â€“2013. <i>Neuro-Oncology</i> , 2016, 18, v1-v75. | 1.2 | 995 |
| 12 | Epidemiologic and Molecular Prognostic Review of Glioblastoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1985-1996. | 2.5 | 933 |
| 13 | CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014â€“2018. <i>Neuro-Oncology</i> , 2021, 23, iii1-iii105. | 1.2 | 804 |
| 14 | Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007â€“2011. <i>Neuro-Oncology</i> , 2015, 16, x1-x36. | 1.2 | 414 |
| 15 | Brain and other central nervous system tumor statistics, 2021. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 381-406. | 329.8 | 404 |
| 16 | Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014. <i>JAMA Oncology</i> , 2018, 4, 1254. | 7.1 | 373 |
| 17 | Association of Maximal Extent of Resection of Contrast-Enhanced and Nonâ€“Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 495. | 7.1 | 325 |
| 18 | Epidemiology of Gliomas. <i>Cancer Treatment and Research</i> , 2015, 163, 1-14. | 0.5 | 319 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Childhood Brain Tumor Epidemiology: A Brain Tumor Epidemiology Consortium Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2716-2736. | 2.5 | 290 |
| 20 | Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. <i>Nature Genetics</i> , 2017, 49, 789-794. | 21.4 | 259 |
| 21 | American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. <i>Neuro-Oncology</i> , 2016, 18, i1-i50. | 1.2 | 212 |
| 22 | Brain metastases: epidemiology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 149, 27-42. | 1.8 | 198 |
| 23 | Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. <i>Neuro-Oncology</i> , 2015, 17, 1166-1173. | 1.2 | 169 |
| 24 | The elderly left behind—changes in survival trends of primary central nervous system lymphoma over the past 4 decades. <i>Neuro-Oncology</i> , 2018, 20, 687-694. | 1.2 | 159 |
| 25 | Risk factors for childhood and adult primary brain tumors. <i>Neuro-Oncology</i> , 2019, 21, 1357-1375. | 1.2 | 150 |
| 26 | Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007. <i>Neuro-Oncology</i> , 2017, 19, 1553-1564. | 1.2 | 146 |
| 27 | Epidemiology of Brain Tumors. <i>Neurologic Clinics</i> , 2018, 36, 395-419. | 1.8 | 135 |
| 28 | Descriptive epidemiology of pituitary tumors in the United States, 2004–2009. <i>Journal of Neurosurgery</i> , 2014, 121, 527-535. | 1.6 | 130 |
| 29 | Females have the survival advantage in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 576-577. | 1.2 | 122 |
| 30 | Incidence of vestibular schwannomas in the United States. <i>Journal of Neuro-Oncology</i> , 2015, 124, 223-228. | 2.9 | 105 |
| 31 | The descriptive epidemiology of atypical teratoid/rhabdoid tumors in the United States, 2001-2010. <i>Neuro-Oncology</i> , 2014, 16, 1392-1399. | 1.2 | 100 |
| 32 | Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. <i>Cancer</i> , 2015, 121, 102-112. | 4.1 | 98 |
| 33 | Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. <i>Neuro-Oncology</i> , 2016, 18, 70-77. | 1.2 | 90 |
| 34 | Current State of Our Knowledge on Brain Tumor Epidemiology. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 329-335. | 4.2 | 86 |
| 35 | Sex Differences in Cancer Incidence and Survival: A Pan-Cancer Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1389-1397. | 2.5 | 82 |
| 36 | Epidemiology of Intracranial Gliomas. <i>Progress in Neurological Surgery</i> , 2018, 30, 1-11. | 1.3 | 78 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Survivorship in adults with malignant brain and other central nervous system tumor from 2000–2014. <i>Neuro-Oncology</i> , 2018, 20, vii6-vii16. | 1.2 | 76 |
| 38 | Glioma incidence and survival variations by county-level socioeconomic measures. <i>Cancer</i> , 2019, 125, 3390-3400. | 4.1 | 68 |
| 39 | Understanding inherited genetic risk of adult glioma – a review. <i>Neuro-Oncology Practice</i> , 2016, 3, 10-16. | 1.6 | 62 |
| 40 | Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. <i>Journal of Neuro-Oncology</i> , 2017, 135, 433-441. | 2.9 | 62 |
| 41 | Descriptive Epidemiology of Spinal Meningiomas in the United States. <i>Spine</i> , 2015, 40, E886-E889. | 2.0 | 56 |
| 42 | Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. <i>Scientific Reports</i> , 2018, 8, 7352. | 3.3 | 56 |
| 43 | Sex-specific gene and pathway modeling of inherited glioma risk. <i>Neuro-Oncology</i> , 2019, 21, 71-82. | 1.2 | 52 |
| 44 | Descriptive epidemiology of germ cell tumors of the central nervous system diagnosed in the United States from 2006 to 2015. <i>Journal of Neuro-Oncology</i> , 2019, 143, 251-260. | 2.9 | 52 |
| 45 | Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010. <i>Neuro-Oncology</i> , 2017, 19, now252. | 1.2 | 48 |
| 46 | The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone. <i>Neuro-Oncology</i> , 2018, 20, 295-298. | 1.2 | 46 |
| 47 | Genome-Wide Methylation Analyses in Glioblastoma Multiforme. <i>PLoS ONE</i> , 2014, 9, e89376. | 2.5 | 45 |
| 48 | Estimating the annual frequency of synchronous brain metastasis in the United States 2010–2013: a population-based study. <i>Journal of Neuro-Oncology</i> , 2017, 134, 55-64. | 2.9 | 44 |
| 49 | Epidemiology of Brain and Other CNS Tumors. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 68. | 4.2 | 43 |
| 50 | Incidence patterns for primary malignant spinal cord gliomas: a Surveillance, Epidemiology, and End Results study. <i>Journal of Neurosurgery: Spine</i> , 2011, 14, 742-747. | 1.7 | 41 |
| 51 | Comparative Brain and Central Nervous System Tumor Incidence and Survival between the United States and Taiwan Based on Population-Based Registry. <i>Frontiers in Public Health</i> , 2016, 4, 151. | 2.7 | 40 |
| 52 | Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians. <i>Neuro-Oncology Practice</i> , 2022, 9, 165-182. | 1.6 | 40 |
| 53 | Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995–2015. <i>Neuro-Oncology</i> , 2020, 22, 301-302. | 1.2 | 39 |
| 54 | Impact of atopy on risk of glioma: a Mendelian randomisation study. <i>BMC Medicine</i> , 2018, 16, 42. | 5.5 | 38 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009. <i>Cancer Medicine</i> , 2015, 4, 608-619. | 2.8 | 36 |
| 56 | Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma. <i>Neuro-Oncology Practice</i> , 2019, 6, 451-462. | 1.6 | 36 |
| 57 | Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). <i>Journal of Neuro-Oncology</i> , 2016, 130, 31-42. | 2.9 | 35 |
| 58 | Influence of obesity-related risk factors in the aetiology of glioma. <i>British Journal of Cancer</i> , 2018, 118, 1020-1027. | 6.4 | 32 |
| 59 | Models of epigenetic age capture patterns of DNA methylation in glioma associated with molecular subtype, survival, and recurrence. <i>Neuro-Oncology</i> , 2018, 20, 942-953. | 1.2 | 31 |
| 60 | Epidemiology and Molecular Epidemiology. <i>Neurosurgery Clinics of North America</i> , 2019, 30, 1-16. | 1.7 | 30 |
| 61 | Glioblastoma as an age-related neurological disorder in adults. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab125. | 0.7 | 30 |
| 62 | Response to "The epidemiology of glioma in adults: a 'state of the science' review". <i>Neuro-Oncology</i> , 2015, 17, 624-626. | 1.2 | 29 |
| 63 | Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. <i>Neuro-Oncology</i> , 2022, 24, 302-310. | 1.2 | 29 |
| 64 | Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017. <i>Neuro-Oncology</i> , 2021, 23, 990-998. | 1.2 | 28 |
| 65 | The epidemiology of central and extraventricular neurocytoma in the United States between 2006 and 2014. <i>Journal of Neuro-Oncology</i> , 2019, 143, 123-127. | 2.9 | 27 |
| 66 | Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. <i>Neuro-Oncology</i> , 2022, 24, 1989-2000. | 1.2 | 27 |
| 67 | Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma. <i>Cancer Research</i> , 2019, 79, 2065-2071. | 0.9 | 26 |
| 68 | Family History of Cancer in Benign Brain Tumor Subtypes Versus Gliomas. <i>Frontiers in Oncology</i> , 2012, 2, 19. | 2.8 | 25 |
| 69 | Methylation markers of malignant potential in meningiomas. <i>Journal of Neurosurgery</i> , 2013, 119, 899-906. | 1.6 | 25 |
| 70 | Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. <i>PLoS ONE</i> , 2019, 14, e0219724. | 2.5 | 25 |
| 71 | Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011. <i>Journal of Neuro-Oncology</i> , 2015, 123, 43-51. | 2.9 | 24 |
| 72 | Integrated genomic analysis of survival outliers in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now269. | 1.2 | 23 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Mendelian randomisation study of the relationship between vitamin D and risk of glioma. <i>Scientific Reports</i> , 2018, 8, 2339. | 3.3 | 23 |
| 74 | Lifetime Occurrence of Brain Metastases Arising from Lung, Breast, and Skin Cancers in the Elderly: A SEER-Medicare Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 917-925. | 2.5 | 23 |
| 75 | Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. <i>International Journal of Cancer</i> , 2020, 146, 739-748. | 5.1 | 23 |
| 76 | Age-specific genome-wide association study in glioblastoma identifies increased proportion of lower grade glioma-like features associated with younger age. <i>International Journal of Cancer</i> , 2018, 143, 2359-2366. | 5.1 | 21 |
| 77 | Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. <i>Cancer Causes and Control</i> , 2019, 30, 477-488. | 1.8 | 21 |
| 78 | The epidemiology of spinal schwannoma in the United States between 2006 and 2014. <i>Journal of Neurosurgery: Spine</i> , 2020, 32, 661-666. | 1.7 | 21 |
| 79 | A comparison of relative survival and cause-specific survival methods to measure net survival in cancer populations. <i>Cancer Medicine</i> , 2018, 7, 4773-4780. | 2.8 | 20 |
| 80 | Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT. <i>Journal of Neuro-Oncology</i> , 2019, 144, 53-63. | 2.9 | 19 |
| 81 | Gene markers in brain tumors: What the epileptologist should know. <i>Epilepsia</i> , 2013, 54, 25-29. | 5.1 | 18 |
| 82 | Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma. <i>Neuro-Oncology</i> , 2017, 19, 1503-1510. | 1.2 | 18 |
| 83 | Relative survival after diagnosis with a primary brain or other central nervous system tumor in the National Program of Cancer Registries, 2004 to 2014. <i>Neuro-Oncology Practice</i> , 2020, 7, 306-312. | 1.6 | 18 |
| 84 | Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report. <i>Journal of Neuro-Oncology</i> , 2017, 133, 17-25. | 2.9 | 17 |
| 85 | Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors. <i>Neuro-Oncology Practice</i> , 2019, 6, 330-339. | 1.6 | 17 |
| 86 | Primary brain and other central nervous system tumors in Appalachia: regional differences in incidence, mortality, and survival. <i>Journal of Neuro-Oncology</i> , 2019, 142, 27-38. | 2.9 | 16 |
| 87 | European genetic ancestry associated with risk of childhood ependymoma. <i>Neuro-Oncology</i> , 2020, 22, 1637-1646. | 1.2 | 16 |
| 88 | Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Gastroenterology</i> , 2020, 159, 2065-2076.e1. | 1.3 | 16 |
| 89 | Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 555-562. | 2.5 | 15 |
| 90 | Genetic predisposition to longer telomere length and risk of childhood, adolescent and adult-onset ependymoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 173. | 5.2 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | The Epidemiology of Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 23-42. | 2.2 | 15 |
| 92 | Conditional survival after diagnosis with malignant brain and central nervous system tumor in the United States, 1995â€“2012. <i>Journal of Neuro-Oncology</i> , 2016, 128, 419-429. | 2.9 | 14 |
| 93 | Is mortality due to primary malignant brain and other central nervous system tumors decreasing?. <i>Journal of Neuro-Oncology</i> , 2017, 133, 265-275. | 2.9 | 14 |
| 94 | An updated histology recode for the analysis of primary malignant and nonmalignant brain and other central nervous system tumors in the Surveillance, Epidemiology, and End Results Program. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa175. | 0.7 | 14 |
| 95 | The Shared Genetic Architectures Between Lung Cancer and Multiple Polygenic Phenotypes in Genome-Wide Association Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1156-1164. | 2.5 | 13 |
| 96 | Testing for causality between systematically identified risk factors and glioma: a Mendelian randomization study. <i>BMC Cancer</i> , 2020, 20, 508. | 2.6 | 12 |
| 97 | Partitioned glioma heritability shows subtype-specific enrichment in immune cells. <i>Neuro-Oncology</i> , 2021, 23, 1304-1314. | 1.2 | 12 |
| 98 | Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. <i>Neuro-Oncology</i> , 2014, 16, 1333-1340. | 1.2 | 11 |
| 99 | International Differences in Treatment and Clinical Outcomes for High Grade Glioma. <i>PLoS ONE</i> , 2015, 10, e0129602. | 2.5 | 11 |
| 100 | Whole Tumor Histogram Analysis Using DW MRI in Primary Central Nervous System Lymphoma Correlates with Tumor Biomarkers and Outcome. <i>Cancers</i> , 2019, 11, 1506. | 3.7 | 11 |
| 101 | Pilocytic astrocytoma: Where do they belong in cancer reporting?. <i>Neuro-Oncology</i> , 2019, 22, 298-300. | 1.2 | 11 |
| 102 | Racial/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US. <i>Journal of Neuro-Oncology</i> , 2021, 152, 603-615. | 2.9 | 10 |
| 103 | The shared genetic architecture between epidemiological and behavioral traits with lung cancer. <i>Scientific Reports</i> , 2021, 11, 17559. | 3.3 | 10 |
| 104 | Do race and age vary in non-malignant central nervous system tumor incidences in the United States?. <i>Journal of Neuro-Oncology</i> , 2017, 134, 269-277. | 2.9 | 8 |
| 105 | Brain tumor biobanking in the precision medicine era: building a high-quality resource for translational research in neuro-oncology. <i>Neuro-Oncology Practice</i> , 2017, 4, 220-228. | 1.6 | 5 |
| 106 | Association of metabolic syndrome with glioblastoma: a retrospective cohort study and review. <i>Neuro-Oncology Practice</i> , 2020, 7, 541-548. | 1.6 | 5 |
| 107 | Role of Ethnicity and Geographic Location on Glioblastoma IDH1/IDH2 Mutations. <i>World Neurosurgery</i> , 2021, 149, e894-e912. | 1.3 | 5 |
| 108 | Exposure to radon and heavy particulate pollution and incidence of brain tumors. <i>Neuro-Oncology</i> , 2023, 25, 407-417. | 1.2 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Epidemiology of Pineoblastoma in the United States, 2000-2017. Neuro-Oncology Practice, 2022, 9, 149-157. | 1.6 | 4 |
| 110 | Epidemiology of Glioblastoma and Trends in Glioblastoma Survivorship. , 2016, , 11-19. | | 3 |
| 111 | Association between urbanicity and surgical treatment among patients with primary glioblastoma in the United States. Neuro-Oncology Practice, 2020, 7, 299-305. | 1.6 | 3 |
| 112 | Proteins inform survival-based differences in patients with glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa039. | 0.7 | 3 |
| 113 | The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. Neuro-Oncology Advances, 2021, 3, vdab035. | 0.7 | 3 |
| 114 | Aligning the Central Brain Tumor Registry of the United States (CBTRUS) histology groupings with current definitions. Neuro-Oncology Practice, 2022, 9, 317-327. | 1.6 | 3 |
| 115 | Epidemiology and Etiology of Glioblastoma. Molecular Pathology Library, 2021, , 3-19. | 0.1 | 1 |
| 116 | Prevalence of autoimmunity and atopy in US adults with glioblastoma and meningioma. Neuro-Oncology, 0, , . | 1.2 | 1 |
| 117 | Abstract 129: Integrated genomic analysis of survival outliers in glioblastoma. , 2016, , . | | 0 |
| 118 | Integrating germline and somatic genomic analysis to probe etiological mechanism in malignant glioma. Oncotarget, 2019, 10, 3086-3087. | 1.8 | 0 |
| 119 | Abstract 4173: Previously identified common glioma risk SNPs are associated with familial glioma. , 2019, , . | | 0 |
| 120 | Abstract 2745: Tumor microenvironment and host genetics impact glioma progression in a Collaborative Cross-based orthotopic allograft model. , 2019, , . | | 0 |